Bispecific
Bispecific Test
Imvotamab Biosimilar Introduction This is an IgM-based CD20xCD3 bispecific antibody T cell engager (TCE) for the treatment of B cell non-Hodgkin’s lymphoma (NHL). Preclinical research demonstrates that imvotamab may have advantages over IgG bispecific antibodies including greater binding power to CD20 expressing cancer cells especially when CD20 expression has been Read more